FIELD: biotechnology.
SUBSTANCE: neutralizing antibodies to a type I receptor of human pituitary adenylate cyclase-activating polypeptide (hereinafter – PAC1), as well as pharmaceutical compositions containing such antibodies are proposed. Polynucleotides, expression vectors, and host cells for the production of antibodies are also proposed. In addition, methods for the treatment or prevention of conditions related to headache, such as migraine and cluster headache, using the specified neutralizing antibodies, are described.
EFFECT: invention provides increased inhibitory activity against human PAC1.
44 cl, 20 dwg, 24 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CD40L ANTIBODIES AND METHODS OF TREATING CD40L RELATED DISEASES AND DISORDERS | 2016 |
|
RU2727646C2 |
| IMMUNE TOLERANCE INDUCING ANTIBODIES, INDUCED LYMPHOCYTES AND THERAPEUTIC AGENT/METHOD OF CELL THERAPY USING INDUCED LYMPHOCYTES | 2019 |
|
RU2816592C2 |
| EphA4 ANTIBODY | 2016 |
|
RU2719158C2 |
| ANTIBODIES AGAINST CXCR2 AND THEIR USE | 2019 |
|
RU2807067C2 |
| CD47-ANTIGEN-BINDING UNIT AND ITS USE | 2018 |
|
RU2780859C2 |
| ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN, AND USE THEREOF | 2020 |
|
RU2825304C2 |
| COMPOSITION FOR PREVENTION AND TREATMENT OF SKIN DISEASE CONTAINING SUBSTANCE SPECIFICALLY BINDING WITH VIMENTINE DERIVATIVE PEPTIDE | 2018 |
|
RU2751486C1 |
| ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
| ANTI-CLDN ANTIBODY, ITS PHARMACEUTICAL COMPOSITION AND A METHOD OF ITS DETECTION | 2020 |
|
RU2801315C2 |
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
